Eisai Co., Ltd. announced that its U.S. subsidiary Eisai Inc. has received approval from the FDA for an indication expansion...
Data at the International Epilepsy Congress in Istanbul show Fycompa (perampanel), from Eisai, may significantly reduce seizure frequency, both in...
The FDA has approved Fycompa (perampanel) CIII Oral Suspension, from Eisai, as adjunctive therapy for the treatment of partial-onset seizures...
Results from the final pivotal Phase III study and long term Phase III extension study of Epilepsy drug Fycompa (perampanel),...
Eisai has resubmitted a new drug application for its perampanel, for which it is seeking approval in this key market...
Eisai announced that the results of its Phase III trial (Study 332) for Fycompa (perampanel) CIII have been published in...
Eisai Inc. announced the initiation of two multi-center, global Phase III clinical trials assessing Fycompa (perampanel) CIII in two different...
New data from two studies demonstrate the efficacy and safety of once-daily anti-epilepsy treatment Fycompa (perampanel), from Eisai, in the...
Fycompa (perampanel) is indicated for the adjunctive treatment of - partial-onset seizures (POS) with or without secondarily generalised seizures in patients from 4 years of age and older. - primary generalised tonic-clonic (PGTC) seizures in patients from 7 years of age and older with idiopathic generalised epilepsy (IGE).
Eisai has announced that a Phase III clinical trial (study 332) of Fycompa (perampanel) has met its primary endpoint in...